A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 29,400 shares of OLMA stock, worth $180,810. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,400
Previous 53,200 44.74%
Holding current value
$180,810
Previous $575,000 38.96%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.41 - $16.46 $247,758 - $391,748
-23,800 Reduced 44.74%
29,400 $351,000
Q2 2024

Aug 09, 2024

BUY
$8.73 - $13.99 $464,436 - $744,268
53,200 New
53,200 $575,000
Q4 2023

Feb 13, 2024

SELL
$10.53 - $17.14 $1.44 Million - $2.35 Million
-136,889 Reduced 44.09%
173,611 $2.44 Million
Q3 2023

Nov 14, 2023

BUY
$8.19 - $12.98 $144,144 - $228,448
17,600 Added 6.01%
310,500 $3.84 Million
Q2 2023

Aug 11, 2023

BUY
$3.22 - $9.65 $114,954 - $344,505
35,700 Added 13.88%
292,900 $2.65 Million
Q1 2023

May 12, 2023

SELL
$2.55 - $4.97 $22,950 - $44,730
-9,000 Reduced 3.38%
257,200 $892,000
Q4 2022

Feb 13, 2023

SELL
$2.27 - $3.76 $259,461 - $429,768
-114,300 Reduced 30.04%
266,200 $652,000
Q3 2022

Nov 14, 2022

BUY
$2.72 - $5.88 $256,675 - $554,872
94,366 Added 32.98%
380,500 $1.05 Million
Q2 2022

Aug 12, 2022

BUY
$2.04 - $4.61 $79,156 - $178,877
38,802 Added 15.69%
286,134 $1.17 Million
Q1 2022

May 13, 2022

BUY
$3.89 - $9.43 $962,121 - $2.33 Million
247,332 New
247,332 $1.05 Million
Q4 2021

Feb 11, 2022

SELL
$8.75 - $30.71 $856,625 - $3.01 Million
-97,900 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$22.96 - $30.13 $2.25 Million - $2.95 Million
97,900 New
97,900 $2.7 Million

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $249M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.